title: Matrix metalloproteinase-7 and matrix metalloproteinase-9 in pediatric multiple sclerosis.
abstract: Matrix metalloproteinases and their tissue inhibitors play a key role in the pathogenesis of adult-onset multiple sclerosis, and were suggested as biomarkers of response to interferon-β, an established treatment in multiple sclerosis. However, data regarding pediatric population are scarce. We determined serum levels of matrix metalloproteinase-7, matrix metalloproteinase-9, and tissue inhibitor of matrix metalloproteinase-1 in children, and evaluated effects of interferon-β therapy on these measures. Serum samples from 14 children with relapsing, remitting multiple sclerosis at baseline and at month 12, and from 15 controls, were collected. Interferon-β treatment was initiated in eight patients. Mean serum matrix metalloproteinase-9 levels and matrix metalloproteinase-9/tissue inhibitor of matrix metalloproteinase-1 ratio were higher in patients compared with controls, and were reduced significantly in treated patients at month 12, but did not change in untreated patients. Mean matrix metalloproteinase-7 levels were lower in patients compared with controls, and increased significantly in the treated group, but did not change significantly in the untreated group. In pediatric multiple sclerosis, a shift in matrix metalloproteinase-9/tissue inhibitor of matrix metalloproteinase-1 balance toward proteolytic activity is evident, and interferon-β therapy demonstrates a beneficial effect on this disturbed balance.
authors.affiliation: Department of Pediatric Neurology, Medical Faculty, Gazi University, Ankara, Turkey. drunsalyilmaz@yahoo.com
authors.forename: Ünsal
authors.initials: Ü
authors.lastname: Yılmaz
authors.forename: Yılmaz
authors.initials: Y
authors.lastname: Unsal
authors.forename: Kıvılcım
authors.initials: K
authors.lastname: Gücüyener
authors.forename: Gücüyener
authors.initials: G
authors.lastname: Kıvılcım
authors.forename: Ayşegül
authors.initials: A
authors.lastname: Atak
authors.forename: Atak
authors.initials: A
authors.lastname: Ayşegül
authors.forename: Arzu
authors.initials: A
authors.lastname: Aral
authors.forename: Aral
authors.initials: A
authors.lastname: Arzu
authors.forename: Esra
authors.initials: E
authors.lastname: Gürkaş
authors.forename: Gürkaş
authors.initials: G
authors.lastname: Esra
authors.forename: Ercan
authors.initials: E
authors.lastname: Demir
authors.forename: Demir
authors.initials: D
authors.lastname: Ercan
authors.forename: Ayşe
authors.initials: A
authors.lastname: Serdaroğlu
authors.forename: Serdaroğlu
authors.initials: S
authors.lastname: Ayşe
mesh_terms: D000293:Adolescent; D002648:Child; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D016899:Interferon-beta / Q000627:therapeutic use; D008297:Male; D020783:Matrix Metalloproteinase 7 / Q000097:blood*; D020780:Matrix Metalloproteinase 9 / Q000097:blood*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000097:blood* / Q000201:enzymology*; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000097:blood; D016896:Treatment Outcome
chemical_list: D007155:Immunologic Factors; C560822:TIMP1 protein, human; D019715:Tissue Inhibitor of Metalloproteinase-1; D016899:Interferon-beta; D020783:Matrix Metalloproteinase 7; D020780:Matrix Metalloproteinase 9